
Opinion|Videos|October 14, 2024
Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor and taxane treatments, highlighting the role of PSMA PET imaging in treatment sequencing and patient selection.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix
5







